- Home
- ARVN vs ADAM Comparison
ARVN vs ADAM Comparison
Compare ARVN & ADAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARVN | ADAM |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.0M | 762.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ARVN | ADAM |
|---|---|---|
| Price | $13.49 | $8.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 3 |
| Target Price | ★ $15.57 | $9.17 |
| AVG Volume (30 Days) | ★ 743.8K | 583.9K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.16% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.94 | $5.10 |
| P/E Ratio | ★ N/A | $41.51 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.90 | $6.45 |
| 52 Week High | $18.93 | $8.76 |
Technical Indicators
Market Signals| Indicator | ARVN | ADAM |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 58.25 |
| Support Level | $11.10 | $6.85 |
| Resistance Level | $13.97 | $8.67 |
| Average True Range (ATR) | 0.83 | 0.25 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 81.83 | 71.34 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About ADAM Adamas Trust Inc.
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing and managing primarily mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit sensitive single-family and multi-family assets.